Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease

BACKGROUND: Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy appr...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Saudi Med
Hoofdauteurs: Mohammed, Mohammed Hassan A., Agouba, Rihab, Obaidy, Islam El, Alhabshan, Fahad, Abu-Sulaiman, Riyadh
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: King Faisal Specialist Hospital and Research Centre 2021
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7868616/
https://ncbi.nlm.nih.gov/pubmed/33550912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5144/0256-4947.2021.31
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items